Skip to main content
. Author manuscript; available in PMC: 2015 Mar 3.
Published in final edited form as: J Alzheimers Dis. 2014;41(2):535–549. doi: 10.3233/JAD-132789

Figure 2. Aβ immunization and LXR agonist treatment did not affect amyloid plaque level and insoluble amyloid in depositing APP23 mice.

Figure 2

Amyloid pathology was assessed in APP23 mice immunized with HJ3.4 antibody plus/minus LXR agonist T0 treated for 50 days. A, B, C and D, X-34 staining was used to assess amyloid plaques in hippocampus (panel A and C) and cortex (panel B and D). On A and B, are presented plaques levels as % X-34 positive area and on C and D, are presented number of X-34 positive plaques. Means were analyzed by one-way ANOVA, no statistical significance for A, B, C and D. Two-way ANOVA showed no interaction and no significant main effects in hippocampus or cortex for A, B, C and D. E and F, 6E10 staining was used to assess diffuse amyloid plaques in hippocampus (panel E) and cortex (panel F). On panels E and F are presented 6E10 plaques as % positive area. Means were analyzed by one-way ANOVA and there was no significant difference between treatments and control group. Two-way ANOVA showed no interaction in hippocampus and cortex, however there was a significant main effect of LXR in hippocampus [F(1,40)=4.41, p <0.05]. For all panels N=6–13 mice per group.